21
Aug

FDA Issues Final Guidance on Therapeutic Equivalence

Today, the FDA issued the final guidance titled Evaluation of Therapeutic Equivalence (here). The guidance is essentially identical to one with the same title issued in July 2022. There are only a few changes from the draft guidance, which include revisions to reflect an additional process by which applicants of certain 505(b)(2) applications may request […]

Read More
14
Aug

FDA Updates Container Closure System Packaging Guidance

The Agency has issued a 37-page draft guidance (here), that describes FDA’s current thinking regarding a wide range of issues regarding various container closure systems, packaging components and testing requirements to ensure that the proposed container closure system is appropriate for the proposed drug product. FDA says that when finalized, this draft guidance will “supersede […]

Read More
24
Jul

FDA Approves First Acetaminophen/Naproxen Combination Product for Pain

Today, the FDA approved a combination of acetaminophen and naproxen sodium tablets, 325 mg/110 mg for minor pain as an over-the-counter product for 12-hour pain relief. FDA says in a press release (here): “This nonprescription product is indicated for the temporary relief of minor aches and pains due to headache, backache, muscular aches, toothache, menstrual […]

Read More
17
Jul

Get Your Reading Glasses On – CDER Guidance Plans for 2026 Cite 85 Documents

With four and a half months remaining in fiscal year 2026, the Center for Drug Evaluation and Research (CDER) has published the list of 85 new or revised guidance documents that it plans to release this year! The document (here) categories along with the number of anticipated guidances are as follows: Administrative/Procedural – 8 Artificial […]

Read More
09
Jul

CDMO Growth Creates Data Integrity Risks Across Company Boundaries

The pharmaceutical supply chain is no longer just a chain of physical materials, but rather a complex series of data, data-based decisions, and delegated responsibilities for that data. FDA’s CDER FY2024 Site Catalog reported 4,619 manufacturing sites globally, reflecting the broad scale of the regulated manufacturing network supporting the U.S. drug supply. Within that network, […]

Read More
08
Jul

HHS Unified Rule Agenda for 2026

The list is long (here) and there are some interesting regulatory items found in the agenda for FDA. Take some time and peruse them all as I will just highlight a few items of interest in this post. Here are some of the proposed rules that caught my attention: Current Good Manufacturing Practice for Outsourcing […]

Read More
25
Jun

One Adequate and Well-Controlled Study – Be Sure You Meet with the FDA!

The new draft guidance “Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products” (here) provides the industry with a foundation for providing one adequate and well-controlled study with appropriate confirmatory supporting data to satisfy the Agency’s requirement for demonstrating safety and efficacy. While this may, on its face, appear to be a boon […]

Read More
1 2 3 … 35